<DOC>
	<DOCNO>NCT00216580</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety long-acting injectable risperidone treatment patient early stage psychosis</brief_summary>
	<brief_title>A Pilot Study Use Risperidone Long Acting Injectable Treatment Patients With Recent Onset Psychosis</brief_title>
	<detailed_description>Although many schizophrenia patient currently take oral antipsychotic medication , estimate 75 % difficulty adhere daily oral regimen . Long-acting injectable formulation may eliminate need daily medication enhance patient compliance treatment regimen . This study pilot project demonstrate long-acting risperidone use safely effectively treat patient early stage psychosis . It open-label , single-arm study patient recent onset schizophrenia , schizophreniform disorder , schizoaffective disorder . There 3 phase : Wash-out Phase 7 day , current psychotropic medication discontinue ; Oral Treatment Phase , begin 1 week first injection continue 3 week thereafter , risperidone tablet take ; Long-Acting Injectable Treatment Phase , injection give every 2 week 24 month . Assessments effectiveness include Positive Negative Syndrome Scale ( PANSS ) , scale measurement symptom schizophrenia ; time initiation treatment relapse ; Calgary Depression Scale Schizophrenia ( CDSS ) , assess symptom major depressive disorder patient schizophrenia ; Clinical Global Impression ( CGI ) scale . Safety assessment include incidence adverse event Extrapyramidal Symptom Rating Scale ( ESRS ) score throughout study ; clinical laboratory test ( hematology chemistry ) vital sign ( pulse , blood pressure , temperature ) state interval . Risperidone oral tablet daily ( 1 milligram [ mg ] , 2mg , 3mg [ maximum ] ) 1 week first injection 3 wks . Risperidone injection ( 25mg , 37.5mg , 50mg [ max ] ) every 2 week 24 month . Doses may increase decreased investigator 's discretion .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Meet criterion Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) schizophreniform disorder , schizophrenia , schizoaffective disorder longer 12 month , two hospitalization psychosis patient , lifetime , expose maximum 12 week antipsychotic medication patient require least 12 month treatment DSMIV axis I diagnosis schizophreniform disorder , schizophrenia , schizoaffective disorder patient require treatment mood stabilizer antidepressant study initiation alcohol drug abuse dependence , accord DSMIV criterion history drug allergy , drug hypersensitivity ( include risperidone ) , neuroleptic malignant syndrome , rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness previous treatment injectable antipsychotic medication pregnant nursing female , lack adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Intramuscular injection</keyword>
	<keyword>Antipsychotic agent</keyword>
	<keyword>Long-acting risperidone</keyword>
	<keyword>Schizophreniform disorder</keyword>
	<keyword>Schizoaffective disorder</keyword>
</DOC>